Patents Represented by Attorney Ye Hua
-
Patent number: 7906529Abstract: Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.Type: GrantFiled: December 19, 2007Date of Patent: March 15, 2011Assignee: Serenex, Inc.Inventors: Kenneth He Huang, Jeron Eaves, Gunnar Hanson, James Veal, Thomas Barta, Lifeng Geng, Lindsay Hinkley
-
Patent number: 7884117Abstract: Carbonylamino Pyrrolopyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.Type: GrantFiled: December 12, 2006Date of Patent: February 8, 2011Assignee: Pfizer Inc.Inventors: Junhun Zhang, Anle Yang, Susan Elizabeth Kephart, Liming Dong, Chuangxing Guo, Yufeng Hong, Mary Catherine Johnson, Indrawan James McAlpine, Jayashree Tikhe, Haitao Li
-
Patent number: 7678803Abstract: The current invention is directed toward compounds and pharmaceutically acceptable salts of Formula I wherein Q1 is CR1, Q2 is N, Q4 and Q5 are each CR1, Q3 is CR2, X1 is N or CRc, Y is CRc, X2 and X3 are each C(R5)(R6), R7 is O. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer The current invention is also directed toward pharmaceutical compositions comprising compounds of the invention.Type: GrantFiled: August 24, 2007Date of Patent: March 16, 2010Assignee: Serenex, Inc.Inventors: Kenneth He Huang, James Veal, Thomas Barta, Emilie D. Smith, Wei Ma, Andy Ommen
-
Patent number: 7320996Abstract: The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors of the formula I: wherein R1, R2, R3, R4, R5, R6, and R7 are defined herein, in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors.Type: GrantFiled: August 15, 2002Date of Patent: January 22, 2008Assignees: Sugen, Inc, Pharmacia CorporationInventors: Jaime Masferrer, Parul Doshi, Julie Cherrington
-
Patent number: 7300943Abstract: The invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein R1, R2, and R3 are as defined herein; pharmaceutical compositions thereof; and use thereof in the treatment of, inter alia, conditions, diseases, and symptoms such as diabetes, dementia, Alzheimer's Disease, stroke, schizophrenia, depression, hair loss, and cancer.Type: GrantFiled: June 23, 2004Date of Patent: November 27, 2007Assignee: Pfizer Inc.Inventor: Travis T. Wager
-
Patent number: 7300944Abstract: The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein R1, R2 and R3 are as defined herein; pharmaceutical formulations thereof; and use thereof in the treatment of, inter alia, conditions, diseases, and symptoms such as bipolar disorder, diabetes, dementia, Alzheimer's Disease, stroke, schizophrenia, depression, hair loss, and cancer.Type: GrantFiled: June 23, 2004Date of Patent: November 27, 2007Assignee: Pfizer Inc.Inventors: Daniel W. Kung, Travis T. Wager
-
Patent number: 7256189Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.Type: GrantFiled: August 28, 2006Date of Patent: August 14, 2007Assignees: Sugen, Inc., Pharmacia & Upjohn CompanyInventors: Huiping Guan, Congxin Liang, Li Sun, Peng Cho Tang, Chung Chen Wei, Tomas Vojkovsky, Qingwu (Alan) Jin, Paul M. Herrinton, Michael A. Mauragis
-
Patent number: 7247627Abstract: The invention relates to non-hygroscopic salts of 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, such as maleate salts, and to crystalline polymorphs of these salts. The invention further relates to pharmaceutical compositions of 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide salts, and methods of treating disorders such as cancer using such compositions.Type: GrantFiled: September 30, 2004Date of Patent: July 24, 2007Assignee: Pharmacia & Upjohn CompanyInventors: Andrei Blasko, Qingwu Jin, Qun Lu, Michael A. Mauragis, Dian Song, Brenda S. Vonderwell
-
Patent number: 7232912Abstract: Indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.Type: GrantFiled: April 22, 2005Date of Patent: June 19, 2007Assignee: Agouron Pharmaceuticals, Inc.Inventors: Siegfried Heinz Reich, Ted Michael Bleckman, Susan Elizabeth Kephart, William Henry Romines, III, Michael Brennan Wallace
-
Patent number: 7202245Abstract: The present invention provides compounds of formula (I) the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein Ra, Rb, R1, and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.Type: GrantFiled: March 22, 2004Date of Patent: April 10, 2007Assignee: Pfizer Inc.Inventors: John W. Benbow, Margaret Y. Chu-Moyer, Daniel W. Kung
-
Patent number: 7132533Abstract: Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3 and R4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.Type: GrantFiled: July 22, 2005Date of Patent: November 7, 2006Assignee: Agouron Pharmaceuticals, Inc.Inventors: Suzanne Benedict, Michael Bennett, Sacha Ninkovic, Min Teng, Eugene Rui, Fen Wang, Yong Wang, Jinjiang Zhu
-
Patent number: 7112603Abstract: The present invention is directed to prodrugs of certain 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.Type: GrantFiled: February 10, 2004Date of Patent: September 26, 2006Assignee: Agouron Pharmaceuticals, Inc.Inventors: Malcolm Wilson Moon, Walter Morozowich, Ping Gao, Marcel Koenig
-
Patent number: 7022846Abstract: Metabolites of a matrix metalloproteinase inhibitor prinomastat and their synthesis. These metabolites are: (3S)-N-hydroxy-4-(4-((1-oxy-pyrid-4-yl)oxy)benzenesulfonyl)-2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide (M6); (3S)-2,2-dimethyl-1,1-dioxo-4-[4-(1-oxy-pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M7); (3S)-2,2-dimethyl-4-[4-(1-oxypyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M8); (3S)-2,2-dimethyl-1,1-dioxo-4-[4-(pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M2); and (3S)-2,2-dimethyl-4-[4-(pyridin-4yloxy)-benzenesulfonyl)-thiomorphpline-3-carboxylic acid amide (M3).Type: GrantFiled: June 10, 2003Date of Patent: April 4, 2006Assignee: Agouron Pharmaceuticals, Inc.Inventors: Michael A. Ouellette, Barbara C. M. Potts, Jayaram K. Srirangam, Anthony R. Tibbetts, Kanyin E. Zhang